Peng Yuan, Li Lin, Huang Mengge, Duan Changzhu, Zhang Luyu, Chen Junxia
Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, PR China; The First Clinical College, Chongqing Medical University, Chongqing 400016, PR China.
Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, PR China; Department of Cell Biology and Genetics, Chongqing Medical University, Chongqing 400016, PR China.
Cell Signal. 2014 Dec;26(12):2782-92. doi: 10.1016/j.cellsig.2014.08.021. Epub 2014 Sep 2.
Angiogenin (ANG), a member of RNase A superfamily, is the only angiogenic factor that possesses ribonucleolytic activity. Recent studies showed that the expression of ANG was elevated in various types of cancers. Accumulating evidence indicates that ANG plays an essential role in cancer progression by stimulating both cancer cell proliferation and tumor angiogenesis. Human ribonuclease inhibitor (RI), a cytoplasmic protein, is constructed almost entirely of leucine rich repeats (LRRs), which are present in a large family of proteins that are distinguished by their display of vast surface areas to foster protein-protein interactions. RI might be involved in unknown biological effects except inhibiting RNase A activity. The experiment demonstrated that RI also could suppress activity of angiogenin (ANG) through closely combining with it in vitro. PI3K/AKT/mTOR signaling pathway exerts a key role in cell growth, survival, proliferation, apoptosis and angiogenesis. We recently reported that up-regulating RI inhibited the growth and induced apoptosis of murine melanoma cells through repression of angiogenin and PI3K/AKT signaling pathway. However, ANG receptors have not yet been identified to date, its related signal transduction pathways are not fully clear and underlying interacting mechanisms between RI and ANG remain largely unknown. Therefore, we hypothesize that RI might combine with intracellular ANG to block its nuclear translocation and regulate PI3K/AKT/mTOR signaling pathway to inhibit biological functions of ANG. Here, we reported for the first time that ANG could interact with RI endogenously and exogenously by using co-immunoprecipitation (Co-IP) and GST pull-down. Furthermore, we observed the colocalization of ANG and RI in cells with immunofluorescence staining under laser confocal microscope. Moreover, through fluorescence resonance energy transfer (FRET) assay, we further confirmed that these two proteins have a physical interaction in living cells. Subsequently, we demonstrated that up-regulating ANG including ANG His37Ala mutant obviously decreased RI expression and activated phosphorylation of key downstream target molecules of PI3K/AKT/mTOR signaling pathway. Finally, up-regulating ANG led to the promotion of tumor angiogenesis, tumorigenesis and metastasis in vivo. Taken together, our data provided a novel mechanism of ANG in regulating PI3K/AKT/mTOR signaling pathway via RI, which suggested a new therapeutic target for cancer therapy.
血管生成素(ANG)是核糖核酸酶A超家族的成员,是唯一具有核糖核酸酶活性的血管生成因子。最近的研究表明,ANG在各种类型的癌症中表达升高。越来越多的证据表明,ANG通过刺激癌细胞增殖和肿瘤血管生成在癌症进展中起重要作用。人核糖核酸酶抑制剂(RI)是一种细胞质蛋白,几乎完全由富含亮氨酸的重复序列(LRR)构成,这些重复序列存在于一大类蛋白质中,其特点是具有广阔的表面积以促进蛋白质-蛋白质相互作用。RI除了抑制核糖核酸酶A的活性外,可能还参与未知的生物学效应。实验表明,RI在体外也能通过与血管生成素(ANG)紧密结合来抑制其活性。PI3K/AKT/mTOR信号通路在细胞生长、存活、增殖、凋亡和血管生成中发挥关键作用。我们最近报道,上调RI通过抑制血管生成素和PI3K/AKT信号通路抑制小鼠黑色素瘤细胞的生长并诱导其凋亡。然而,迄今为止尚未鉴定出ANG受体,其相关信号转导通路尚不完全清楚,RI与ANG之间潜在的相互作用机制仍 largely未知。因此,我们推测RI可能与细胞内的ANG结合,阻断其核转位并调节PI3K/AKT/mTOR信号通路,从而抑制ANG的生物学功能。在此,我们首次报道通过免疫共沉淀(Co-IP)和GST下拉实验表明ANG能在体内外与RI相互作用。此外,我们在激光共聚焦显微镜下用免疫荧光染色观察到ANG和RI在细胞中的共定位。而且,通过荧光共振能量转移(FRET)分析,我们进一步证实这两种蛋白在活细胞中存在物理相互作用。随后,我们证明上调ANG包括ANG His37Ala突变体明显降低RI表达并激活PI3K/AKT/mTOR信号通路关键下游靶分子的磷酸化。最后,上调ANG导致体内肿瘤血管生成、肿瘤发生和转移的促进。综上所述,我们的数据提供了ANG通过RI调节PI3K/AKT/mTOR信号通路的新机制,这为癌症治疗提示了一个新的治疗靶点。